Clinical Research Directory

Inclusion Criteria: Patients: A patient cannot be considered eligible for this study unless ALL of the following conditions are met. * Patient is receiving standard of care treatment for renal cell carcinoma for one of the following indications: 1) NIVO monotherapy as maintenance, after ipilimumab and NIVO induction (up to 4 doses), 2) NIVO monotherapy as single-agent treatment, OR 3) adjuvant PEMBRO monotherapy or combination therapy with belzutifan. Of note, patient does not need to be newly initiating treatment to be eligible for this study. * For patients on NIVO monotherapy or PEMBRO (Groups 2 and 3 above), they must have received at least 1 dose as a standard of care to be eligible * Patient has at least 6 doses of planned treatment left as standard of care that can be given on protocol (either NIVO or PEMBRO) * For example, standard of care for adjuvant PEMBRO is 1 year of therapy which can be given at 3 (17 doses) or 6 (9 doses) week intervals. Patients can enter this trial after starting treatment but must have at least 6 doses of treatment left to be eligible. * For example, standard of care for maintenance NIVO (after ipilimumab + NIVO) is typically about 2 years of therapy. NIVO can be given at 2 (about 52 doses) or 4 week (about 26 doses) intervals. * Age ≥ 18 * Ability to speak and read English because we do not have the resources to translate all materials into other languages * Patient must be able to provide written informed consent, or a legal authorized representative (LAR)/caregiver must be identified to provide consent in cases where the patient cannot. * Patients are unable to receive investigational agents on other clinical trial protocols Providers (Medical Oncologists): * Medical oncologists in the genitourinary medical oncology department will be involved with this study if they are the treating investigator for patients who consent to this study * The medical oncologists who are involved in this will be asked to complete surveys